Ignite Creation Date:
2025-12-24 @ 9:20 PM
Ignite Modification Date:
2025-12-27 @ 11:26 AM
Study NCT ID:
NCT03066804
Status:
COMPLETED
Last Update Posted:
2021-10-11
First Post:
2017-02-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Heart Failure With Preserved Ejection Fraction | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Cardiovascular Diseases | View |
| None | Heart Failure | View |
| None | Heart failure with Preserved Ejection Fraction | View |
| None | NT-proBNP | View |
| None | 6 MWT | View |
| None | KCCQ | View |
| None | SF-36 | View |
| None | NYHA Class | View |
| None | LCZ696 | View |
| None | Enalapril | View |
| None | Valsartan | View |
| None | Angiotensin-Converting Enzyme Inhibitors (ACEi) | View |
| None | Angiotensin II Type 1 Receptor Blockers (ARB) | View |
| None | Renin Angiotensin System Inhibitors (RASi) | View |